Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women

@article{Hegazy2014EvaluationOT,
  title={Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women},
  author={Sahar Kamal Hegazy},
  journal={Journal of Bone and Mineral Metabolism},
  year={2014},
  volume={33},
  pages={207-212}
}
Osteoporosis is the most important metabolic bone disease in patients with diabetes mellitus. Several studies have documented that metformin is osteogenic in vitro. In contrast, others showed no effect of metformin on the osteogenic differentiation of bone marrow-derived mesenchymal stem cells. Incretin hormones have received much attention because of their beneficial effects beyond glycemia, including on bone health. The study evaluated the anti-osteoporotic effect of metformin and sitagliptin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Pre-Menopause, Menopause and Beyond

View 20 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2013
View 1 Excerpt

Incretin based therapies: bone protective effects.

Endocrine, metabolic & immune disorders drug targets • 2013
View 1 Excerpt

A local glucagon-likepeptide1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262–3272

P Marchetti, R Lupi, +14 authors F Dotta
2012
View 1 Excerpt

Diabetes mellitus and osteoporosis. Incretin as a coordinator of glucose and bone metabolism

Y Yamada
Clin Calcium • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…